Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...

As Israel begins to receive hostages in the fragile Israel-Hamas truce, there is both relief and agony. The October 7 ...

The temporomandibular joint (TMJ) develops from neural crest cells which originate from the neuroectoderm. Based on the scientific hypothesis that the ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

The future of oncology lies in people-centered care, prioritizing patient needs and leveraging technology to improve cancer treatment and support systems.

And it is just about 20 minutes to five right here on ABC Drive. And I've got in the studio with me a couple of guys that are ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain.

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

Chronic pain is a global health challenge, with current treatment options often limited by side effects, addiction risk, and diminished effectiveness over time. In a new study, Yale researchers ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...